Latest Advanced Cell Tech (ACTC) Headlines Gl
Post# of 48
Posted On: 03/08/2014 4:50:49 PM
Latest Advanced Cell Tech (ACTC) Headlines
Global Cell Therapy Market & Pipeline Insight Research Report
M2 - Tue Mar 04, 3:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/5kmmgq/global_cell) has announced the addition of the "Global Cell Therapy Market & Pipeline Insight" report to their offering. Research in cell therapy is transforming the future of medicine. As the life of a human being begins as a cell, these cells undergo a highly complex set of events and finally those few stems become capable of self-renewal and differentiation and develop into the specialized cells in the body. Cell therapy research also offers significant potential for restructuring the method of medical practice. Over the past 3-5 years, a more complex therapeutic modality has been is emerging as cell therapies which have been developed to treat diseases which are not amenable to treatment with more classical pharmaceutical or biopharmaceutical products. This market offers the promise of successfully regenerating damaged tissues and organs in the body by replacing the damaged tissue and/or by stimulating the body's own repair mechanisms to heal previously irreparable tissues. With their rising popularity, these therapies are becoming more cost effective and efficient. The global market for cell therapy was valued at close to USD 2.5 Billion in 2012. With continuous advances and developments in this field of medicine, the global cell therapy market is expected to grow at a high rate of 20-22% to reach approximately USD 8 Billion by 2018. Several products and technologies of cell-based therapies are in the R&D pipeline are expected to enter the market during the forecast period, thus resulting in an increased growth rate. It is most likely that the new improved technologies would revolutionize the area of bio-pharma and personalized medicine. Development of sophisticated automation devices for cell expansion and culture process for use in the treatment is one of the emerging trends of ACT market. With the cell-based therapies growing by leaps and bounds, it is expected that the future years would witness significant advancements in technology in the cell therapy market. Increasing incidence of diseases along with lack of adequate effective treatment for these diseases is most likely to drive the cell therapy technology in developed and developing nations. Among the emerging trends of the global market, the most prominent one is the development of sophisticated automation devices for cell expansion and culture process which could be used in the treatment of life threatening diseases. Global Cell Therapy Market & Pipeline Insight Report Highlights & Findings: - Introduction to Cell therapy - Global Cell Therapy Market Overview - Global Cell Therapy Market Dynamics - Cell Therapy Pipeline by Phase, Country & Target Indications - Cell Therapy Drugs in Pipeline: More Than 200 - Highest Number of Drugs in Preclinical Stage: 73 - Number of Drugs in Phase I/II Stage: 35 - Key Market: US - Majority Cell therapies For Cancer Treatment Companies Mentioned - Advanced Cell Technology - Amgen - California Stem Cell - Celgene Corporation - Cytomedix - Fibrocell Science - Genzyme - NeoStem - Novartis - Stemedica Cell Technologies For more information visit http://www.researchandmarkets.com/research/5k...lobal_cell About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
OTC Daily Alert Stock Watch - Advanced Cell Technology, Inc. (OTCQB: ACTC)
WorldStockWire - Wed Feb 05, 4:30AM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Advanced Cell Technology Announces Change in Management
Business Wire - Wed Jan 22, 7:30AM CST
Advanced Cell Technology (OTC:ACTC) today announced that Gary Rabin will leave the Chief Executive Officer position, effective immediately. The board has appointed the Company's CFO and Executive Vice President of Corporate Development, Edward Myles, as interim President. The board will initiate a search for a permanent CEO.
2013 Report on the International Regenerative Medicine Markets
M2 - Mon Jan 13, 8:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/3gvqj4/regenerative) has announced the addition of the "2013 Report on the International Regenerative Medicine Markets" report to their offering. Astounding new advancements in the ability to repair or replace damaged human tissue and organ functions are being made. Whereas before, remedies for damaged tissue or organ functions due to congenital deformities, injuries, diseases or simple wear-and-tear relied upon either the body's ability to repair itself (or not), or a surgeon's skilled hands. Now, the area of regenerative medicine promises to revolutionize humanity's ability to remediate countless physical maladies that have perpetually afflicted humans and other animals. Compared to a select few life forms--like the starfish--man-made solutions for tissue repair and organ replacement haven't come close to nature's solutions. And where there once was no solution even offered by nature, researchers are now at the cusp of overcoming such limitations by "2013 Report on the International Regenerative Medicine Markets", enables the reader gain in-depth knowledge about ongoing tissue engineering and stem cell therapy research programs carried out in universities and other research centers. Moreover, this analysis profiles the leading companies developing regenerative medicine solutions. Key Topics Covered: 1. Overview 2. Regenerative Medicines: An Overview of Segments 3. Regenerative Medicine: The Next Evolution of Medical Treatment 4. Recent Advances in Regenerative Medicine and Stem Cell Research 5. Stem Cell Industry Highlights 6. Regenerative Medicines: A Brief Update from Selected Countries 7. Market Analysis for Regenerative Medicine Sector 8. Stem Cell Industry 9. Business Models and Requirements for a Successful Regenerative Medicine Industry 10. Company Profiles Companies Mentioned: - Aastrom Biosciences, Inc. - Advanced Cell Technology, Inc. (ACT) - Aldagen, Inc. - BeFutur Biotechnologies - Cardio BioSciences - CardioPolymers, Inc. - Develogen AG - Effector Cell Institute, Inc (ECI) - Epistem plc - FivePrime Therapeutics, Inc. - Forticell Bioscience, Inc. - Geron Corporation - Hydra Biosciences, Inc. - Intercytex Group plc - Japan Tissue Engineering, Co., Ltd. - Karocell Tissue Engineering AB - LifeCell - MaxCyte, Inc. - Mesoblast Ltd. - NanoCor's Products - Olympus Terumo Biomaterials Corporation - Pervasis Therapeutics, Inc. - RegeneRx - SyntheMed, Inc. - Thermogenesis Corp. - t cure GmbH For more information visit http://www.researchandmarkets.com/research/3g...generative
Clearlake Capital Invests in PrimeSport
Marketwire - Wed Jan 08, 3:47PM CST
PrimeSport, Inc. ("PrimeSport" or the "Company") and Clearlake Capital Group, L.P. (together with its affiliates, "Clearlake") today announced that Clearlake has acquired a majority stake in PrimeSport, a leading sports travel and entertainment management company.
Strategy Analytics: CES 2014: 56 percent of US consumers would buy UHD TV in next two years
PR Newswire - Wed Jan 08, 2:58PM CST
CES -- Strategy Analytics' new ConsumerMetrix survey carried out over the past few weeks with 2024 US consumers found very strong interest in UHD TV. 19 percent of people said they would be very likely to buy a UHDTV and 37 percent somewhat likely within the next two years. Only 24 percent said they would be unlikely to buy one.
New Year, New Codes 2014 CPT(R) Coding Updates; VitalWare Hosts Free Webinar Reviewing Significant Coding Changes
Marketwire - Tue Jan 07, 2:46PM CST
On January 14, 2014 and January 16, 2014, VitalWare will host complimentary hour-long webinars introducing and reviewing the significant changes in the 2014 CPT(R) and HCPCS code set updates.
Esri's Location Platform Brings the Power of Place to Microsoft Dynamics CRM
PR Newswire - Tue Jan 07, 1:45PM CST
Esri today announced the release of an enhanced Esri Maps for Microsoft Dynamics CRM. The software adds new analytical perspectives for retailers across the omni-channel. From a single store to the entire supply-chain, users can collaborate to author and share analytical intelligence on customers, stores, products, markets, and the competition with a wealth of demographic data for 120 countries.
Celtic Bank Hires Michael Caron as Vice President Business Development
PR Newswire - Tue Jan 07, 11:04AM CST
Celtic Bank is pleased to announce that Michael Caron has been hired as Vice President of Business Development in the Asset-Based Lending Group at Celtic Bank. Caron will be focused on business development of the bank's asset-based lending and factoring programs in the Northeast United States. Caron will report to Daniel Godfrey, Senior Vice President of Asset-Based Lending at Celtic Bank.
Heineken N.V. to recommend appointment of Deloitte as its auditor as of 2015
Thomson Reuters ONE - Fri Dec 20, 1:03AM CST
Amsterdam, 20 December 2013 - Heineken N.V. (HEINEKEN) today announced that its Supervisory Board will recommend to the 2014 Annual General Meeting of Shareholders the appointment of Deloitte as the company's auditor with effect from the 2015 financial year.
Heineken N.V. to nominate Mr. Jean-Marc Huet as Supervisory Board member
Thomson Reuters ONE - Fri Dec 20, 1:01AM CST
Amsterdam, 20 December 2013 - Heineken N.V. announced today that it will propose to the Annual General Meeting of Shareholders (AGM) on 24 April 2014 that Mr. Jean-Marc Huet be appointed a member of the Supervisory Board of Heineken N.V. If approved, Mr. Huet will join the Audit Committee.
Advanced Cell Technology Announces Release of New Edition of Definitive Resource in Tissue Engineering
Business Wire - Wed Dec 18, 7:30AM CST
Advanced Cell Technology, Inc. ("ACT"; OTCBB:ACTC), a leader in the field of regenerative medicine, announced today that its chief scientific officer, Robert Lanza, M.D., and Robert Langer, Sc.D., Koch Institute Professor at MIT and Scientific Chair of ACT's Board of Directors, have released the fourth edition of "Principles of Tissue Engineering" (Academic Press/Elsevier), the widely-recognized definitive resource in the field of tissue engineering. The 1936-page volume includes contributions from 20 members of the National Academies of Science, Engineering, and Institute of Medicine, as well as dozens of pioneers in the fields of stem cells, tissue engineering, and regenerative medicine.
2013 Report on the International Stem Cells Market - Includes Forecast to 2018
M2 - Wed Dec 18, 6:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/732xpm/stem_cells_market) has announced the addition of the "2013 Report on the International Stem Cells Market - Includes Forecast to 2018" report to their offering. "2013 Report on the International Stem Cells Market - Includes Forecast to 2018", highlights the market shares of key players in 2011. The company profiles for some of the key players, namely Advanced Cell Technology Inc., STEMCELL Technologies Inc., Cellular Engineering Technologies Inc., BioTime Inc., Aastrom Biosciences Inc. and California Stem Cell Inc. in terms of company overview, financial overview, business strategies, recent developments and product portfolio is also covered. The global stem cells market is categorized into the following segments: - Stem Cells Market by Products - Adult Stem Cells - Hematopoietic Stem Cells - Mesenchymal Stem Cells - Neuronal Stem Cells - Dental Stem Cells - Umbilical Cord Stem Cells - Human Embryonic Stem Cells - Induced Pluripotent Stem Cells - Natural Rosette Cells - Very Small Embryonic Like Stem Cells - Stem Cells Market by Technology - Cell Acquisition - Bone Marrow Harvest - Apheresis - Umbilical Blood Cord - Cell Production - Therapeutic Cloning - In Vitro Fertilization - Isolation - Cell Culture - Cryopreservation - Expansion and Sub-Culture - Stem Cells Market by Applications - Regenerative Medicine - Neurological Disorders - Orthopedics - Cancer - Hematological disorders - Cardiovascular diseases Stem Cells Market by Geography - North America - Europe - Asia - Rest of the World (RoW) Key Topics Covered: 1 Preface 1.1 Report Description 1.2 Research Methodology 2 Executive Summary 3 Market Overview 3.1 Market Trends and Future Outlook 3.2 Market Dynamics 3.3 Market Attractiveness 4 Global Stem Cells Market, By Products 4.1 Market Segmentation: Global Stem Cells Market, By Products 4.2 Overview 4.3 Adult Stem Cells Market, 2010 - 2018 (USD Billion) 4.4 Human Embryonic Stem Cells Market, 2010 - 2018 (USD Billion) 4.5 Induced Pluripotent Stem Cells Market, 2010 - 2018 (USD Billion) 4.6 Rat Neural Stem Cells Market, 2010 - 2018 (USD Billion) 4.7 Very Small Embryonic-Like Stem Cells Market, 2010 - 2018 (USD Billion) 5 Global Stem Cells Market, By Technology 6 Global Stem Cells Market, By Application 7 Global Stem Cells Market, By Geography 8 Competitive Landscape 9 Company Profiles Companies Mentioned: - Advanced Cell Technology - Angel Biotechnology - Bioheart - Biotime Inc. - Brainstorm Cell Therapeutics - California Stem Cell Inc. - Celgene Corporation Inc. - Cellartis AB - Cellular Engineering Technologies - Cytori Therapeutics Inc. - Osiris Therapeutics - Stemcelltechnologies Inc. For more information visit http://www.researchandmarkets.com/research/73...lls_market
Advanced Cell Technology Appoints Eddy Anglade M.D. Executive Vice President of Clinical Development
Business Wire - Thu Dec 12, 7:30AM CST
Advanced Cell Technology, Inc. ("ACT"; OTCBB:ACTC), a leader in the field of regenerative medicine, today announced the appointment of Eddy Anglade, M.D., to the newly created position of Executive Vice President of Clinical Development. Dr. Anglade is an ophthalmologist and an experienced pharmaceutical executive with more than 16 years of experience overseeing all elements of clinical trials and regulatory affairs.
News and Updates on ACTC, HIPP, AXPW and HEMP
ACCESSWIRE - Thu Nov 14, 4:07AM CST
News and Updates on Advanced Cell Technology Inc. (OTC:ACTC), Hipcricket, Inc. (OTC:HIPP), Axion Power International Inc (OTC:AXPW) and Hemp, Inc. (OTC:HEMP).
Advanced Cell Technology Announces 2013 Third Quarter Results
Business Wire - Tue Nov 12, 3:00PM CST
--Company Expects to Release "Top Line" Interim Data by Year End
Advanced Cell Technology to Host Conference Call to Discuss 2013 Third Quarter Results and Provide a Corporate Update on Tuesday, November 12th
Business Wire - Tue Nov 12, 10:17AM CST
Advanced Cell Technology, Inc. ("ACT"; OTCBB:ACTC), a leader in the field of regenerative medicine, announced today that it will release its third quarter financial results for the period ended September 30, 2013 after the market closes and hold a conference call on Tuesday, November 12th, 2013 at 4:30 p.m. EST during which it will discuss these results and provide a corporate update.
Latest Equity Reports on NWTR, NAMG, GSAT and ACTC
ACCESSWIRE - Fri Nov 01, 12:23AM CDT
New Western Energy Corp (OTC:NWTR), North American Oil & Gas Corp (OTC:NAMG), Globalstar Inc. (OTC:GSAT) and Advanced Cell Technology Inc (OTC:ACTC) have been added to our OTC watch list.
ACT's Dr. Robert Lanza to Deliver Keynote Lecture at the World Conference on Regenerative Medicine
Business Wire - Mon Oct 21, 7:30AM CDT
Advanced Cell Technology, Inc. ("ACT"; OTCBB:ACTC), a leader in the field of regenerative medicine, announced today that its chief scientific officer, Robert Lanza, M.D., will be delivering a Keynote lecture at the "World Conference on Regenerative Medicine" being held in Leipzig, Germany October 23-25th. The Conference is considered one of the world's largest and most influential events in stem cells and regenerative medicine, and provides a platform that brings scientists with an academic, clinical and industrial background together. Dr. Lanza's Lecture, entitled "ES and iPS Cells - Moving into the Clinic," will take place at 9:00 a.m. at the Congress Center Leipzig.
Global Cell Therapy Market & Pipeline Insight Research Report
M2 - Tue Mar 04, 3:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/5kmmgq/global_cell) has announced the addition of the "Global Cell Therapy Market & Pipeline Insight" report to their offering. Research in cell therapy is transforming the future of medicine. As the life of a human being begins as a cell, these cells undergo a highly complex set of events and finally those few stems become capable of self-renewal and differentiation and develop into the specialized cells in the body. Cell therapy research also offers significant potential for restructuring the method of medical practice. Over the past 3-5 years, a more complex therapeutic modality has been is emerging as cell therapies which have been developed to treat diseases which are not amenable to treatment with more classical pharmaceutical or biopharmaceutical products. This market offers the promise of successfully regenerating damaged tissues and organs in the body by replacing the damaged tissue and/or by stimulating the body's own repair mechanisms to heal previously irreparable tissues. With their rising popularity, these therapies are becoming more cost effective and efficient. The global market for cell therapy was valued at close to USD 2.5 Billion in 2012. With continuous advances and developments in this field of medicine, the global cell therapy market is expected to grow at a high rate of 20-22% to reach approximately USD 8 Billion by 2018. Several products and technologies of cell-based therapies are in the R&D pipeline are expected to enter the market during the forecast period, thus resulting in an increased growth rate. It is most likely that the new improved technologies would revolutionize the area of bio-pharma and personalized medicine. Development of sophisticated automation devices for cell expansion and culture process for use in the treatment is one of the emerging trends of ACT market. With the cell-based therapies growing by leaps and bounds, it is expected that the future years would witness significant advancements in technology in the cell therapy market. Increasing incidence of diseases along with lack of adequate effective treatment for these diseases is most likely to drive the cell therapy technology in developed and developing nations. Among the emerging trends of the global market, the most prominent one is the development of sophisticated automation devices for cell expansion and culture process which could be used in the treatment of life threatening diseases. Global Cell Therapy Market & Pipeline Insight Report Highlights & Findings: - Introduction to Cell therapy - Global Cell Therapy Market Overview - Global Cell Therapy Market Dynamics - Cell Therapy Pipeline by Phase, Country & Target Indications - Cell Therapy Drugs in Pipeline: More Than 200 - Highest Number of Drugs in Preclinical Stage: 73 - Number of Drugs in Phase I/II Stage: 35 - Key Market: US - Majority Cell therapies For Cancer Treatment Companies Mentioned - Advanced Cell Technology - Amgen - California Stem Cell - Celgene Corporation - Cytomedix - Fibrocell Science - Genzyme - NeoStem - Novartis - Stemedica Cell Technologies For more information visit http://www.researchandmarkets.com/research/5k...lobal_cell About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
OTC Daily Alert Stock Watch - Advanced Cell Technology, Inc. (OTCQB: ACTC)
WorldStockWire - Wed Feb 05, 4:30AM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Advanced Cell Technology Announces Change in Management
Business Wire - Wed Jan 22, 7:30AM CST
Advanced Cell Technology (OTC:ACTC) today announced that Gary Rabin will leave the Chief Executive Officer position, effective immediately. The board has appointed the Company's CFO and Executive Vice President of Corporate Development, Edward Myles, as interim President. The board will initiate a search for a permanent CEO.
2013 Report on the International Regenerative Medicine Markets
M2 - Mon Jan 13, 8:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/3gvqj4/regenerative) has announced the addition of the "2013 Report on the International Regenerative Medicine Markets" report to their offering. Astounding new advancements in the ability to repair or replace damaged human tissue and organ functions are being made. Whereas before, remedies for damaged tissue or organ functions due to congenital deformities, injuries, diseases or simple wear-and-tear relied upon either the body's ability to repair itself (or not), or a surgeon's skilled hands. Now, the area of regenerative medicine promises to revolutionize humanity's ability to remediate countless physical maladies that have perpetually afflicted humans and other animals. Compared to a select few life forms--like the starfish--man-made solutions for tissue repair and organ replacement haven't come close to nature's solutions. And where there once was no solution even offered by nature, researchers are now at the cusp of overcoming such limitations by "2013 Report on the International Regenerative Medicine Markets", enables the reader gain in-depth knowledge about ongoing tissue engineering and stem cell therapy research programs carried out in universities and other research centers. Moreover, this analysis profiles the leading companies developing regenerative medicine solutions. Key Topics Covered: 1. Overview 2. Regenerative Medicines: An Overview of Segments 3. Regenerative Medicine: The Next Evolution of Medical Treatment 4. Recent Advances in Regenerative Medicine and Stem Cell Research 5. Stem Cell Industry Highlights 6. Regenerative Medicines: A Brief Update from Selected Countries 7. Market Analysis for Regenerative Medicine Sector 8. Stem Cell Industry 9. Business Models and Requirements for a Successful Regenerative Medicine Industry 10. Company Profiles Companies Mentioned: - Aastrom Biosciences, Inc. - Advanced Cell Technology, Inc. (ACT) - Aldagen, Inc. - BeFutur Biotechnologies - Cardio BioSciences - CardioPolymers, Inc. - Develogen AG - Effector Cell Institute, Inc (ECI) - Epistem plc - FivePrime Therapeutics, Inc. - Forticell Bioscience, Inc. - Geron Corporation - Hydra Biosciences, Inc. - Intercytex Group plc - Japan Tissue Engineering, Co., Ltd. - Karocell Tissue Engineering AB - LifeCell - MaxCyte, Inc. - Mesoblast Ltd. - NanoCor's Products - Olympus Terumo Biomaterials Corporation - Pervasis Therapeutics, Inc. - RegeneRx - SyntheMed, Inc. - Thermogenesis Corp. - t cure GmbH For more information visit http://www.researchandmarkets.com/research/3g...generative
Clearlake Capital Invests in PrimeSport
Marketwire - Wed Jan 08, 3:47PM CST
PrimeSport, Inc. ("PrimeSport" or the "Company") and Clearlake Capital Group, L.P. (together with its affiliates, "Clearlake") today announced that Clearlake has acquired a majority stake in PrimeSport, a leading sports travel and entertainment management company.
Strategy Analytics: CES 2014: 56 percent of US consumers would buy UHD TV in next two years
PR Newswire - Wed Jan 08, 2:58PM CST
CES -- Strategy Analytics' new ConsumerMetrix survey carried out over the past few weeks with 2024 US consumers found very strong interest in UHD TV. 19 percent of people said they would be very likely to buy a UHDTV and 37 percent somewhat likely within the next two years. Only 24 percent said they would be unlikely to buy one.
New Year, New Codes 2014 CPT(R) Coding Updates; VitalWare Hosts Free Webinar Reviewing Significant Coding Changes
Marketwire - Tue Jan 07, 2:46PM CST
On January 14, 2014 and January 16, 2014, VitalWare will host complimentary hour-long webinars introducing and reviewing the significant changes in the 2014 CPT(R) and HCPCS code set updates.
Esri's Location Platform Brings the Power of Place to Microsoft Dynamics CRM
PR Newswire - Tue Jan 07, 1:45PM CST
Esri today announced the release of an enhanced Esri Maps for Microsoft Dynamics CRM. The software adds new analytical perspectives for retailers across the omni-channel. From a single store to the entire supply-chain, users can collaborate to author and share analytical intelligence on customers, stores, products, markets, and the competition with a wealth of demographic data for 120 countries.
Celtic Bank Hires Michael Caron as Vice President Business Development
PR Newswire - Tue Jan 07, 11:04AM CST
Celtic Bank is pleased to announce that Michael Caron has been hired as Vice President of Business Development in the Asset-Based Lending Group at Celtic Bank. Caron will be focused on business development of the bank's asset-based lending and factoring programs in the Northeast United States. Caron will report to Daniel Godfrey, Senior Vice President of Asset-Based Lending at Celtic Bank.
Heineken N.V. to recommend appointment of Deloitte as its auditor as of 2015
Thomson Reuters ONE - Fri Dec 20, 1:03AM CST
Amsterdam, 20 December 2013 - Heineken N.V. (HEINEKEN) today announced that its Supervisory Board will recommend to the 2014 Annual General Meeting of Shareholders the appointment of Deloitte as the company's auditor with effect from the 2015 financial year.
Heineken N.V. to nominate Mr. Jean-Marc Huet as Supervisory Board member
Thomson Reuters ONE - Fri Dec 20, 1:01AM CST
Amsterdam, 20 December 2013 - Heineken N.V. announced today that it will propose to the Annual General Meeting of Shareholders (AGM) on 24 April 2014 that Mr. Jean-Marc Huet be appointed a member of the Supervisory Board of Heineken N.V. If approved, Mr. Huet will join the Audit Committee.
Advanced Cell Technology Announces Release of New Edition of Definitive Resource in Tissue Engineering
Business Wire - Wed Dec 18, 7:30AM CST
Advanced Cell Technology, Inc. ("ACT"; OTCBB:ACTC), a leader in the field of regenerative medicine, announced today that its chief scientific officer, Robert Lanza, M.D., and Robert Langer, Sc.D., Koch Institute Professor at MIT and Scientific Chair of ACT's Board of Directors, have released the fourth edition of "Principles of Tissue Engineering" (Academic Press/Elsevier), the widely-recognized definitive resource in the field of tissue engineering. The 1936-page volume includes contributions from 20 members of the National Academies of Science, Engineering, and Institute of Medicine, as well as dozens of pioneers in the fields of stem cells, tissue engineering, and regenerative medicine.
2013 Report on the International Stem Cells Market - Includes Forecast to 2018
M2 - Wed Dec 18, 6:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/732xpm/stem_cells_market) has announced the addition of the "2013 Report on the International Stem Cells Market - Includes Forecast to 2018" report to their offering. "2013 Report on the International Stem Cells Market - Includes Forecast to 2018", highlights the market shares of key players in 2011. The company profiles for some of the key players, namely Advanced Cell Technology Inc., STEMCELL Technologies Inc., Cellular Engineering Technologies Inc., BioTime Inc., Aastrom Biosciences Inc. and California Stem Cell Inc. in terms of company overview, financial overview, business strategies, recent developments and product portfolio is also covered. The global stem cells market is categorized into the following segments: - Stem Cells Market by Products - Adult Stem Cells - Hematopoietic Stem Cells - Mesenchymal Stem Cells - Neuronal Stem Cells - Dental Stem Cells - Umbilical Cord Stem Cells - Human Embryonic Stem Cells - Induced Pluripotent Stem Cells - Natural Rosette Cells - Very Small Embryonic Like Stem Cells - Stem Cells Market by Technology - Cell Acquisition - Bone Marrow Harvest - Apheresis - Umbilical Blood Cord - Cell Production - Therapeutic Cloning - In Vitro Fertilization - Isolation - Cell Culture - Cryopreservation - Expansion and Sub-Culture - Stem Cells Market by Applications - Regenerative Medicine - Neurological Disorders - Orthopedics - Cancer - Hematological disorders - Cardiovascular diseases Stem Cells Market by Geography - North America - Europe - Asia - Rest of the World (RoW) Key Topics Covered: 1 Preface 1.1 Report Description 1.2 Research Methodology 2 Executive Summary 3 Market Overview 3.1 Market Trends and Future Outlook 3.2 Market Dynamics 3.3 Market Attractiveness 4 Global Stem Cells Market, By Products 4.1 Market Segmentation: Global Stem Cells Market, By Products 4.2 Overview 4.3 Adult Stem Cells Market, 2010 - 2018 (USD Billion) 4.4 Human Embryonic Stem Cells Market, 2010 - 2018 (USD Billion) 4.5 Induced Pluripotent Stem Cells Market, 2010 - 2018 (USD Billion) 4.6 Rat Neural Stem Cells Market, 2010 - 2018 (USD Billion) 4.7 Very Small Embryonic-Like Stem Cells Market, 2010 - 2018 (USD Billion) 5 Global Stem Cells Market, By Technology 6 Global Stem Cells Market, By Application 7 Global Stem Cells Market, By Geography 8 Competitive Landscape 9 Company Profiles Companies Mentioned: - Advanced Cell Technology - Angel Biotechnology - Bioheart - Biotime Inc. - Brainstorm Cell Therapeutics - California Stem Cell Inc. - Celgene Corporation Inc. - Cellartis AB - Cellular Engineering Technologies - Cytori Therapeutics Inc. - Osiris Therapeutics - Stemcelltechnologies Inc. For more information visit http://www.researchandmarkets.com/research/73...lls_market
Advanced Cell Technology Appoints Eddy Anglade M.D. Executive Vice President of Clinical Development
Business Wire - Thu Dec 12, 7:30AM CST
Advanced Cell Technology, Inc. ("ACT"; OTCBB:ACTC), a leader in the field of regenerative medicine, today announced the appointment of Eddy Anglade, M.D., to the newly created position of Executive Vice President of Clinical Development. Dr. Anglade is an ophthalmologist and an experienced pharmaceutical executive with more than 16 years of experience overseeing all elements of clinical trials and regulatory affairs.
News and Updates on ACTC, HIPP, AXPW and HEMP
ACCESSWIRE - Thu Nov 14, 4:07AM CST
News and Updates on Advanced Cell Technology Inc. (OTC:ACTC), Hipcricket, Inc. (OTC:HIPP), Axion Power International Inc (OTC:AXPW) and Hemp, Inc. (OTC:HEMP).
Advanced Cell Technology Announces 2013 Third Quarter Results
Business Wire - Tue Nov 12, 3:00PM CST
--Company Expects to Release "Top Line" Interim Data by Year End
Advanced Cell Technology to Host Conference Call to Discuss 2013 Third Quarter Results and Provide a Corporate Update on Tuesday, November 12th
Business Wire - Tue Nov 12, 10:17AM CST
Advanced Cell Technology, Inc. ("ACT"; OTCBB:ACTC), a leader in the field of regenerative medicine, announced today that it will release its third quarter financial results for the period ended September 30, 2013 after the market closes and hold a conference call on Tuesday, November 12th, 2013 at 4:30 p.m. EST during which it will discuss these results and provide a corporate update.
Latest Equity Reports on NWTR, NAMG, GSAT and ACTC
ACCESSWIRE - Fri Nov 01, 12:23AM CDT
New Western Energy Corp (OTC:NWTR), North American Oil & Gas Corp (OTC:NAMG), Globalstar Inc. (OTC:GSAT) and Advanced Cell Technology Inc (OTC:ACTC) have been added to our OTC watch list.
ACT's Dr. Robert Lanza to Deliver Keynote Lecture at the World Conference on Regenerative Medicine
Business Wire - Mon Oct 21, 7:30AM CDT
Advanced Cell Technology, Inc. ("ACT"; OTCBB:ACTC), a leader in the field of regenerative medicine, announced today that its chief scientific officer, Robert Lanza, M.D., will be delivering a Keynote lecture at the "World Conference on Regenerative Medicine" being held in Leipzig, Germany October 23-25th. The Conference is considered one of the world's largest and most influential events in stem cells and regenerative medicine, and provides a platform that brings scientists with an academic, clinical and industrial background together. Dr. Lanza's Lecture, entitled "ES and iPS Cells - Moving into the Clinic," will take place at 9:00 a.m. at the Congress Center Leipzig.
(0)
(0)